Clinical trials sponsored by Gruppo Oncologico del Nord-Ovest

Phase breakdown

Conditions studied

Recruiting trials led by Gruppo Oncologico del Nord-Ovest

• FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
  NCT06733038 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 24 locations
• Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.
  NCT06897644 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
  NCT05845450 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
  NCT07407465 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations

Common questions

How many trials is Gruppo Oncologico del Nord-Ovest recruiting for?

Gruppo Oncologico del Nord-Ovest is the lead sponsor of 4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.